Top

Published in:

01-12-2008 | Original Article

Defects of FA/BRCA pathway in lymphoma cell lines

Authors: Hui Xiao, Ke Jian Zhang, Bing Xia

Published in: International Journal of Hematology | Issue 5/2008

Abstract

The aim was to find the possible relationship between defects in the FA/BRCA pathway of genomic maintenance and potential pathogenesis of T and B cell lymphoma. We screened 29 cell lines derived from diverse subtypes of lymphoma for possible FA pathway defects. The results indicated: no defect in FANCD2 ubiquitination, BRCA2 and FANCJ expression; absence of FANCN protein in three cell lines: HT, Sudhl4 and JEKO-1. This absence was correlated with enhanced MMC-induced G2 arrest, growth inhibition and high chromosomal breakage rate in the three cell lines. We only found one substitution in HT and JEKO-1 exon-5a fragment: c.1769C > T, p. A590V. But in another lymphoma cell line Sudhl4 with FANCN absence, we have not found any mutation. In conclusion, this mutation maybe the reason which caused FANCN protein expression absent or made the protein very unstable and lose its function in HT and JEKO-1 cell lines.

Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2:446–57. doi:10.1038/35076590.CrossRefPubMed

Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for 2 new genetic subtypes. Blood. 2003;103:2498–503. doi:10.1182/blood-2003-08-2915.CrossRefPubMed

Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003;35:165–70. doi:10.1038/ng1241.CrossRefPubMed

Tischkowitz M, Xia B, Sabbaghian N, et al. Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci USA. 2007;104:6788–93. doi:10.1073/pnas.0701724104.CrossRefPubMedPubMedCentral

Xia B, Dorsman JC, Ameziane N, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39:159–61. doi:10.1038/ng1942.CrossRefPubMed

Reid S, Schindler D, Hanenberg H, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162–4. doi:10.1038/ng1947.CrossRefPubMed

Howlett NG, Taniguchi T, Olson S, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297:606–9. doi:10.1126/science.1073834.CrossRefPubMed

Levitus M, Waisfisz Q, Godthelp BC, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group. J Nat Genet. 2005;37:934–5. doi:10.1038/ng1625.CrossRef

Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25:5875–84. doi:10.1038/sj.onc.1209878.CrossRefPubMed

10.

Hinz JM, Nham PB, Salazar EP, et al. The Fanconi anemia pathway limits the severity of mutagenesis. DNA Repair (Amst). 2006;5:875–84. doi:10.1016/j.dnarep.2006.05.039.CrossRef

11.

D’Andrea AD, Grompe M. The Fanconi anemia/BRCA pathway. Nat Rev Cancer. 2003;3:23–34. doi:10.1038/nrc970.CrossRefPubMed

12.

Venkitaraman AR. Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer. 2004;4:266–76. doi:10.1038/nrc1321.CrossRefPubMed

13.

Joenje H, Lo Ten Foe JR, Oostra AB, et al. Classification of Fanconi anemia patients by complementation analysis: evidence for a fifth genetic subtype. Blood. 1995;86:2156–60.PubMed

14.

Hogervorst FB, Nederlof PM, Gille JJ, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res. 2003;63:1449–53.PubMed

15.

Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9:568–74. doi:10.1038/nm852.CrossRefPubMed

16.

Tischkowitz M, Ameziane N, Waisfisz Q, et al. Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia. Br J Haematol. 2003;123:469–71. doi:10.1046/j.1365-2141.2003.04640.x.CrossRefPubMed

17.

Olopade OI, Wei M. FANCF methylation contributes to chemoselectivity in ovarian cancer. Cancer Cell. 2003;3:417–20. doi:10.1016/S1535-6108(03)00111-9.CrossRefPubMed

18.

Marsit CJ, Liu M, Nelson HH, et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene. 2004;23:1000–4. doi:10.1038/sj.onc.1207256.CrossRefPubMed

19.

Narayan G, Arias-Pulido H, Nandula SV, et al. Promoter hypermethylation of FANCF: disruption of Fanconi anemia-BRCA pathway in cervical cancer. Cancer Res. 2004;64:2994–7. doi:10.1158/0008-5472.CAN-04-0245.CrossRefPubMed

20.

Dhillon VS, Shahid M, Husain SA. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin. Mol Cancer. 2004;3:33. doi:10.1186/1476-4598-3-33.CrossRefPubMedPubMedCentral

21.

Koul S, McKiernan JM, Narayan G, et al. Role of promoter hypermethylation in cisplatin treatment response of male germ cell tumors. Mol Cancer. 2004;3:16. doi:10.1186/1476-4598-3-16.CrossRefPubMedPubMedCentral

22.

van Der Heijden MS, Yeo CJ, Hruban RH, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 2003;63:2585–8.PubMed

23.

van der Heijden MS, Brody JR, Gallmeier E, et al. Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol. 2004;165:651–7.CrossRefPubMedPubMedCentral

24.

Couch FJ, Johnson MR, Rabe K, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005;65:383–6.PubMed

25.

Turner N, Tutt A, Ashworth A. Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 2004;4:814–9. doi:10.1038/nrc1457.CrossRefPubMed

26.

Chen Q, Van der Sluis PC, Boulware D, et al. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood. 2005;106:698–705. doi:10.1182/blood-2004-11-4286.CrossRefPubMedPubMedCentral

27.

Goldsby RE, Perkins SL, Virshup DM, et al. Lymphoblastic lymphoma and excessive toxicity from chemotherapy: an unusual presentation for Fanconi anemia. J Pediatr Hematol Oncol. 1999;21:240–3. doi:10.1097/00043426-199905000-00014.CrossRefPubMed

Title: Defects of FA/BRCA pathway in lymphoma cell lines
Authors: Hui Xiao
Ke Jian Zhang
Bing Xia
Publication date: 01-12-2008
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 5/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-008-0199-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Adhesion-dependent growth of primary adult T cell leukemia cells with down-regulation of HTLV-I p40Tax protein: a novel in vitro model of the growth of acute ATL cells

Hemophagocytic lymphohistiocytosis during maintenance treatment of precursor B-cell acute lymphoblastic leukemia

Increased incidence of iron deficiency anemia secondary to inadequate iron intake in institutionalized, young patients with cerebral palsy

Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9

Human leukocyte antigen-DR negative de novo acute myeloid leukemia with Philadelphia chromosome

Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice intrahepatic engrafted with cord blood-derived CD34+ cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer